Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sakar HealthcareNSE:SAKAR +4.74%60 Gross Margin % is 60.08% as of Mar. 2026, which is 28% above its 10-year median of 46.97. GuruFocus rates NSE:SAKAR with a GF Score™ of 60/100 and a GF Value™ of ₹540.00 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 943 Drug Manufacturers companies, Sakar Healthcare ranks better than 53.34% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Sakar Healthcare had a gross margin of 60.08% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Sakar Healthcare Gross Margin % Related Terms
Sakar Healthcare Gross Margin % Historical Data
* Premium members only.
The historical data trend for Sakar Healthcare's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sakar Healthcare's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sakar Healthcare Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sakar Healthcare's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Sakar Healthcare's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Sakar Healthcare (NSE:SAKAR) has a Gross Margin % of 60.08% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Sakar Healthcare and its competitors. This is 28% above median its historical median of 46.97. Over the past decade, Sakar Healthcare's Gross Margin % has ranged from 41.65 to 53.68. According to the industry distribution chart, Sakar Healthcare ranks #440 out of 943 companies in the Drug Manufacturers industry, placing it in the top 46.7%.
Is Sakar Healthcare's Gross Margin % too high?
Sakar Healthcare's current Gross Margin % of 60.08% is 28% above median its 10-year median of 46.97. Over the past 10 years, this metric has ranged from a low of 41.65 to a high of 53.68. The Drug Manufacturers industry median Gross Margin % is 48.54. Sakar Healthcare's value of 60.08% is 23.8% above this industry median. Based on the distribution chart, Sakar Healthcare ranks #440 out of 943 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sakar Healthcare has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sakar Healthcare's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sakar Healthcare ranks #440 out of 943 companies for Gross Margin %. This puts Sakar Healthcare in the upper half of its industry. The industry median Gross Margin % is 48.54. Sakar Healthcare's value of 60.08% is 23.8% above this benchmark. Historically, Sakar Healthcare's own Gross Margin % has ranged from 41.65 to 53.68 over the past decade. While the company's 10-year median is 46.97 vs. the industry median of 48.54, Sakar Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sakar Healthcare's current Gross Margin % of 60.08% is 23.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Sakar Healthcare and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sakar Healthcare's current Gross Margin % is 60.08%, which is 28% above median its own 10-year median of 46.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sakar Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Sakar Healthcare (NSE:SAKAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹540.00, compared to a current price of ₹904.45 — trading 67.5% above its estimated fair value. The current Gross Margin % is 60.08%, which is 28% above median its 10-year median of 46.97 and 23.8% above the Drug Manufacturers industry median of 48.54. Sakar Healthcare's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Sakar Healthcare (NSE:SAKAR), the current Gross Margin % is 60.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sakar Healthcare (NSE:SAKAR) Overvalued in 2026?
Based on GuruFocus' analysis, Sakar Healthcare stock appears to be overvalued.
The current stock price of ₹904.45 is trading 67.5% above its estimated GF Value™ of ₹540.00.
GuruFocus considers Sakar Healthcare to be Significantly Overvalued.
Key valuation signals for NSE:SAKAR:
Gross Margin %: 60.08% (28% above median its 10-year median of 46.97)
GF Value™: ₹540.00 vs. price of ₹904.45 (67.5% above fair value)
Industry Position: 23.8% above the Drug Manufacturers median (#440 of 943)
No single metric tells the full story. See the NSE:SAKAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sakar Healthcare Ltd is engaged in manufacturing Pharmaceutical products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections. The company offers its products to Sri Lanka, the Philippines, Vietnam, Cambodia, Sudan, Myanmar, Mauritius, Costa Rica, Panama, El Salvador and Paraguay.
60GF Score
Get the complete analysis for NSE:SAKAR
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAKAR has been successfully added to your 
